PTC Therapeutics, Inc. (NASDAQ:PTCT) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.
PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.45. The business had revenue of $47.96 million during the quarter, compared to analysts’ expectations of $28.78 million. PTC Therapeutics had a negative net margin of 88.43% and a negative return on equity of 81.84%. The business’s quarterly revenue was up 206.9% on a year-over-year basis. During the same period last year, the company posted ($1.14) earnings per share. On average, analysts expect PTC Therapeutics to post $-2.49 EPS for the current fiscal year and $-2.52 EPS for the next fiscal year.
Shares of PTC Therapeutics, Inc. (PTCT) opened at 17.57 on Friday. The firm’s market capitalization is $727.20 million. The firm has a 50-day moving average of $18.70 and a 200-day moving average of $17.02. PTC Therapeutics, Inc. has a 12-month low of $4.03 and a 12-month high of $22.00.
ILLEGAL ACTIVITY NOTICE: “PTC Therapeutics, Inc. (PTCT) to Release Quarterly Earnings on Tuesday” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/29/ptc-therapeutics-inc-ptct-to-release-quarterly-earnings-on-tuesday.html.
A number of research analysts have issued reports on the stock. Bank of America Corporation downgraded shares of PTC Therapeutics from a “neutral” rating to an “underperform” rating in a research report on Thursday. Cowen and Company reissued a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday. Royal Bank Of Canada set a $15.00 price objective on shares of PTC Therapeutics and gave the company a “hold” rating in a research report on Wednesday. Zacks Investment Research downgraded shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, J P Morgan Chase & Co downgraded shares of PTC Therapeutics from a “neutral” rating to an “underweight” rating and reduced their target price for the stock from $23.00 to $15.00 in a research report on Monday, October 9th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $17.44.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.